Switching from Mounjaro to Wegovy: what you need to know
Quick answer
The video caption implies the creator is personally switching from tirzepatide (Mounjaro) to semaglutide (Wegovy), two structurally distinct GLP-1 receptor agonist drugs with different mechanisms and different average efficacy profiles in clinical trials. The spoken transcript contains no medical claims and no dosing or clinical information. Switching between these agents requires clinician oversight, a titration plan, and consideration of insurance access, tolerability history, and individual metabolic response.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @chlo_mckernan actually say?
Honestly? Not much about GLP-1 drugs at all. The transcript from this video, which has racked up 222K views under hashtags like #wegovy and #mounjaro, contains zero medical claims. The creator says: "Don't tilt your crowns, it's not for pressure, not for pain, not for people who couldn't handle your shiny." That's motivational language, not medication guidance.
The caption asks "Anyone else doing the switch from mounjaro to wegovy?" which implies the creator is transitioning between tirzepatide (Mounjaro) and semaglutide (Wegovy). But the spoken content doesn't explain why, describe any protocol, or make clinical comparisons. The medical conversation, if there was one, happened in the comments or a follow-up video, not here.
Does the science back this up?
There's nothing to fact-check in the transcript itself, so let's address the implied question the caption raises: is switching from Mounjaro to Wegovy something the evidence supports?
That's genuinely complicated. Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist only. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), tirzepatide at 15mg produced mean weight loss of around 20.9% body weight. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg producing about 14.9% mean weight loss. Those aren't head-to-head numbers, but the gap is real and has been replicated.
Why would someone switch from the drug showing greater average weight loss to one showing less? Insurance coverage, cost, tolerability, and supply issues are all legitimate reasons. The science doesn't say switching is wrong, it just says the two drugs work differently.
What did they get wrong (or right)?
There's nothing medically wrong in the transcript because there's nothing medical in it. The motivational framing, "don't tilt your crowns," reads as community encouragement for people navigating GLP-1 treatment, which is common in the #glp1community space.
What's worth flagging is what's missing. A video with 222K views and a caption explicitly about switching GLP-1 medications carries real informational weight whether the creator intends it or not. People in this community are making real medication decisions, and a caption framing a brand switch as casual or self-directed, without any mention of clinician involvement, is a gap. Switching between these drugs isn't like switching shampoos. Tirzepatide and semaglutide have different receptor profiles, different titration schedules, and different tolerability patterns. A physician or qualified prescriber needs to be part of that conversation.
The creator didn't say anything wrong. But the implied framing of the switch as a personal community experience, rather than a clinician-directed change, is where this kind of content can quietly mislead.
What should you actually know?
If you're considering switching from tirzepatide to semaglutide, or vice versa, here's what the evidence actually says.
- These are not interchangeable drugs. Tirzepatide acts on both GIP and GLP-1 receptors. Semaglutide acts on GLP-1 receptors only. They are not equivalent in mechanism or average outcome data.
- Compounded versions of either drug are not the same as brand-name versions. Formulation, excipients, and dosing accuracy differ. This is not a regulatory technicality, it's a safety issue.
- Switching requires a washout and titration plan. You don't just stop one and start the other at your previous dose. Gastrointestinal side effects can be severe if titration is skipped.
- Insurance and formulary issues are the most common real-world reason people switch, not clinical superiority of one drug over another. If cost or access is driving your decision, talk to your prescriber about prior authorization options before switching.
- The #glp1community on TikTok provides genuine peer support. It also contains a lot of anecdotal dosing advice that has not been reviewed by anyone with a medical license. Use it for community, not clinical guidance.
The bottom line
This video is essentially a caption attached to motivational audio. The creator isn't making medical claims, so there's nothing to debunk. But the framing of a significant medication switch as a relatable community moment, without any mention of prescriber involvement, is worth naming. If you're in the GLP-1 community and considering a switch, the right first call is to your prescriber, not your For You page.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Switching from Mounjaro to Wegovy: what you need to know, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video caption implies the creator is personally switching from tirzepatide (Mounjaro) to semaglutide (Wegovy), two structurally distinct GLP-1 receptor agonist drugs with different mechanisms and different average efficacy profiles in clinical trials.
FormBlends verdict
The video caption implies the creator is personally switching from tirzepatide (Mounjaro) to semaglutide (Wegovy), two structurally distinct GLP-1 receptor agonist drugs with different mechanisms and different average efficacy profiles in clinical trials. The spoken transcript contains no medical claims and no dosing or clinical information. Switching between these agents requires clinician oversight, a titration plan, and consideration of insurance access, tolerability history, and individual metabolic response.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video caption implies the creator is personally switching from tirzepatide (Mounjaro) to semaglutide (Wegovy), two structurally distinct GLP-1 receptor agonist drugs with different mechanisms and different average efficacy profiles in clinical trials. The spoken transcript contains no medical claims and no dosing or clinical information. Switching between these agents requires clinician oversight, a titration plan, and consideration of insurance access, tolerability history, and individual metabolic response.
- The spoken transcript contains zero medical claims about GLP-1 drugs. The fact-check issue lives in the caption and implied framing, not the words.
- Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. Semaglutide (Wegovy/Ozempic) is GLP-1-only. They are not the same class of drug despite both being called GLP-1 medications colloquially.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The spoken transcript contains zero medical claims about GLP-1 drugs. The fact-check issue lives in the caption and implied framing, not the words.
- Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. Semaglutide (Wegovy/Ozempic) is GLP-1-only. They are not the same class of drug despite both being called GLP-1 medications colloquially.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed ~20.9% mean weight loss with tirzepatide 15mg. STEP 1 (Wilding et al., 2021, NEJM) showed ~14.9% with semaglutide 2.4mg. These are not head-to-head trials and individual results vary significantly.
- Switching between GLP-1 agents requires a prescriber-directed titration plan. Starting a new agent at a previously tolerated dose of a different drug is not safe practice.
- Compounded semaglutide and compounded tirzepatide are not equivalent to their brand-name counterparts. The FDA has not approved compounded versions, and formulation differences are a documented safety concern.
- Insurance formulary restrictions are the most common real-world driver of GLP-1 switches, not clinical evidence of superiority. Prescribers can often assist with prior authorization before a switch is made.
- TikTok's #glp1community provides peer support that many patients find valuable, but dosing and switching decisions made on the basis of viral content, rather than clinical consultation, carry real risk.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Chlo 🍒 · TikTok creator
222.2K views on this video
Anyone else doing the switch from mounjaro to wegovy? 😬 #wegovy #mounjaro #glp1 #glp1community #fyppppppppppppppppppppppp
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Chlo 🍒, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.